• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G/A filed

    2/16/21 4:00:38 PM ET
    $BNTX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $BNTX alert in real time by email
    SC 13G/A 1 e21055_bntx-sc13ga.htm

     

    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    SCHEDULE 13G
    Under the Securities Exchange Act of 1934

    (Amendment No. 1)*

     

    BIONTECH SE

    (Name of Issuer)

     

    Ordinary Shares, no par value per share (€1.00 nominal amount)

    (including Ordinary Shares represented by American Depositary Shares)

    (Title of Class of Securities)

     

    09075V102**

    (CUSIP Number)

     

    December 31, 2020

    (Date of Event Which Requires Filing of this Statement)

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

    oRule 13d-1(b)
       
    oRule 13d-1(c)
       
    xRule 13d-1(d)

    *The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.

    **This CUSIP number applies to the American Depositary Shares (“ADSs”) of the Issuer, which are quoted on the Nasdaq Global Select Market under the symbol “BNTX.” Each ADS represents one Ordinary Share. No CUSIP has been assigned to the Ordinary Shares.

    The information required on the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     
     

    SCHEDULE 13G

    CUSIP No.  09075V102    
         
    1

    NAME OF REPORTING PERSONS

     

    MIG Verwaltungs AG

    2

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (See Instructions)

    (a) o

    (b) o

    3

    SEC USE ONLY

     

    4

    CITIZENSHIP OR PLACE OF ORGANIZATION

     

    Germany

    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY
    EACH
    REPORTING
    PERSON
    WITH
    5

    SOLE VOTING POWER

     

    0

    6

    SHARED VOTING POWER

     

    700,845

    7

    SOLE DISPOSITIVE POWER

     

    0

    8

    SHARED DISPOSITIVE POWER

     

    700,845

    9

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

    700,845

    10

    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES
    (See Instructions)

     

    o
    11

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)

     

    0.28%

    12

    TYPE OF REPORTING PERSON (See Instructions)

     

    FI

                                                                                                       

    2
     

    SCHEDULE 13G

    CUSIP No.  09075V102    
         
    1

    NAME OF REPORTING PERSONS

     

    MIG GmbH & Co. Fonds 7 KG

    2

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (See Instructions)

    (a) o

    (b) o

    3

    SEC USE ONLY

     

    4

    CITIZENSHIP OR PLACE OF ORGANIZATION

     

    Germany

    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY
    EACH
    REPORTING
    PERSON
    WITH
    5

    SOLE VOTING POWER

     

    0

    6

    SHARED VOTING POWER

     

    700,845

    7

    SOLE DISPOSITIVE POWER

     

    0

    8

    SHARED DISPOSITIVE POWER

     

    700,845

    9

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

    700,845

    10

    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES
    (See Instructions)

     

    o
    11

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)

     

    0.28%

    12

    TYPE OF REPORTING PERSON (See Instructions)

     

    PN

                                                                                                       

    3
     

    SCHEDULE 13G

    CUSIP No.  09075V102    
         
    1

    NAME OF REPORTING PERSONS

     

    MIG GmbH & Co. Fonds 8 KG

    2

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (See Instructions)

    (a) o

    (b) o

    3

    SEC USE ONLY

     

    4

    CITIZENSHIP OR PLACE OF ORGANIZATION

     

    Germany

    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY
    EACH
    REPORTING
    PERSON
    WITH
    5

    SOLE VOTING POWER

     

    0

    6

    SHARED VOTING POWER

     

    700,845

    7

    SOLE DISPOSITIVE POWER

     

    0

    8

    SHARED DISPOSITIVE POWER

     

    700,845

    9

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

    700,845

    10

    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES
    (See Instructions)

     

    o
    11

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)

     

    0.28%

    12

    TYPE OF REPORTING PERSON (See Instructions)

     

    PN

                                                                                                       
    4
     

    SCHEDULE 13G

    CUSIP No.  09075V102    
         
    1

    NAME OF REPORTING PERSONS

     

    MIG GmbH & Co. Fonds 9 KG

    2

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (See Instructions)

    (a) o

    (b) o

    3

    SEC USE ONLY

     

    4

    CITIZENSHIP OR PLACE OF ORGANIZATION

     

    Germany

    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY
    EACH
    REPORTING
    PERSON
    WITH
    5

    SOLE VOTING POWER

     

    0

    6

    SHARED VOTING POWER

     

    700,845

    7

    SOLE DISPOSITIVE POWER

     

    0

    8

    SHARED DISPOSITIVE POWER

     

    700,845

    9

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

    700,845

    10

    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES
    (See Instructions)

     

    o
    11

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)

     

    0.28%

    12

    TYPE OF REPORTING PERSON (See Instructions)

     

    PN

                                                                                                       

    5
     
    Item 1(a)   Name of Issuer.    
             
        The name of the issuer is BioNTech SE (the “Company”).    
             
    Item 1(b)   Address of Issuer’s Principal Executive Offices.    
             
        The Company’s principal executive office is located at An der Goldgrube 12, D-55131 Mainz, Germany.
             
    Item 2(a)   Name of Person Filing.    
             
       

    This Schedule 13G is being jointly filed by MIG Verwaltungs AG, MIG GmbH & Co. Fonds 7 KG, MIG GmbH & Co. Fonds 8 KG and MIG GmbH & Co. Fonds 9 KG, each of the foregoing, a “Reporting Person,” and collectively, the “Reporting Persons”. MIG Verwaltungs AG manages certain investment funds, including MIG GmbH & Co. Fonds 7 KG, MIG GmbH & Co. Fonds 8 KG and MIG GmbH & Co. Fonds 9 KG.

     

    The Reporting Persons have entered into a Joint Filing Agreement, dated February 14, 2020, a copy of which is incorporated by reference herein to Exhibit on the Schedule 13G filed on February 14, 2020, pursuant to which the Reporting Persons have agreed to file this statement jointly in accordance with the provisions of Rule 13d-1(k)(1) under the Act.

             
    Item 2(b)   Address of Principal Business Office or, if none, Residence.    
             
       

    The address of the principal business office of each of the Reporting Persons is Ismaninger Straße 102

    D-81675 Munich, Germany.

             
    Item 2(c)   Citizenship.    
             
        MIG Verwaltungs AG is a German stock corporation.  Each of MIG GmbH & Co. Fonds 7 KG, MIG GmbH & Co. Fonds 8 KG and MIG GmbH & Co. Fonds 9 KG are German resident limited partnerships (Kommanditgesellschaft).
             
    Item 2(d)   Title of Class of Securities.    
             
        Ordinary Shares, no par value per share (€1.00 nominal amount)
             
    Item 2(e)   CUSIP No.    
             
        09075V102 (This CUSIP number applies to the American Depositary Shares (“ADSs”) of the Issuer, which are quoted on the Nasdaq Global Select Market under the symbol “BNTX.” Each ADS represents one Ordinary Share. No CUSIP has been assigned to the Ordinary Shares.)
             
    Item 3   If this statement is filed pursuant to Rules 13d-1(b), or 13d-2(b), check whether the person filing is a:  
             
        Not applicable.    

    6
     
    Item 4

    Ownership.

     

    Provide the following information regarding the aggregate number and percentage of the class of securities of the issuer identified in Item 1.

     

      (a)

    Amount beneficially owned: 

     

    See the responses to Item 9 on the attached cover pages

     

      (b)

    Percent of class:    

     

    See the responses to Item 11 on the attached cover pages

         
      (c) Number of shares as to which such person has:

     

      (i) Sole power to vote or direct the vote: -0-
         
      (ii) Shared power to vote or direct the vote: See the responses to Item 6 on the attached cover pages

     

      (iii) Sole power to dispose or direct the disposition: -0-

     

      (iv) Shared power to dispose or direct the disposition: See the responses to Item 8 on the attached cover pages
             
        MIG Verwaltungs AG maintains investment and voting power with respect to the Ordinary Shares held by the funds it manages.
             
    Item 5   Ownership of Five Percent or Less of a Class.    
             
        If this statement is being filed to report the fact that as of the date hereof each of the Reporting Persons has ceased to be the beneficial owner of more than five percent of the class of securities, check the following x.
             
    Item 6   Ownership of More Than Five Percent on Behalf of Another Person.
             
        See responses to Item 2(a) and Item 4.
             
    Item 7   Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
             
        See responses to Item 2(a) and Item 4.
             
    Item 8   Identification and Classification of Members of the Group.    
             
        Not applicable.
             
    Item 9   Notice of Dissolution of Group.    
             
        Not applicable.
             
    Item 10   Certification.    
             
        Not Applicable.
    7
     

    SIGNATURE

    After reasonable inquiry and to the best of each of the undersigned’s knowledge and belief, each of the undersigned certifies that the information set forth in this statement is true, complete and correct.

     

    Date: February 16, 2021       MIG Verwaltungs AG
             
            By: 

    /s/ Michael Motschmann /s/ Kristian Schmidt-Garve

            Name: Michael Motschmann, Kristian Schmidt-Garve
            Title: Authorized Signatories
             
    Date: February 16, 2021       MIG GMBH & CO. FONDS 7 KG
           
            By:

    /s/ Michael Motschmann /s/ Kristian Schmidt-Garve

            Name: Michael Motschmann, Kristian Schmidt-Garve
            Title: Authorized Signatories

           
    Date: February 16, 2021       MIG GMBH & CO. FONDS 8 KG
             
            By: 

    /s/ Michael Motschmann /s/ Kristian Schmidt-Garve

            Name: Michael Motschmann, Kristian Schmidt-Garve
            Title: Authorized Signatories
             
    Date: February 16, 2021       MIG GMBH & CO. FONDS 9 KG
             
            By: 

    /s/ Michael Motschmann /s/ Kristian Schmidt-Garve

            Name: Michael Motschmann, Kristian Schmidt-Garve
            Title: Authorized Signatories
    8
    Get the next $BNTX alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $BNTX

    DatePrice TargetRatingAnalyst
    5/27/2026$135.00Neutral → Buy
    UBS
    5/22/2026$96.00Mkt Perform
    Bernstein
    2/2/2026$113.00Outperform → Market Perform
    Leerink Partners
    1/16/2026$142.00Neutral → Buy
    Goldman
    6/5/2025$134.00 → $145.00Buy
    H.C. Wainwright
    5/29/2025$110.00Neutral
    Goldman
    3/13/2025$145.00Buy
    Citigroup
    1/10/2025$172.00Buy
    Truist
    More analyst ratings

    $BNTX
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Chief Financial Officer Zapata Gomez Ramon

    4 - BioNTech SE (0001776985) (Issuer)

    5/13/26 4:09:05 PM ET
    $BNTX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form 4 filed by Officer Ryan James Timothy Patrick

    4 - BioNTech SE (0001776985) (Issuer)

    5/13/26 4:07:47 PM ET
    $BNTX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form 4 filed by Chief Operating Officer Poetting Sierk

    4 - BioNTech SE (0001776985) (Issuer)

    5/13/26 4:05:51 PM ET
    $BNTX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $BNTX
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    The Multi-Billion-Dollar Search for Better Glioblastoma Treatments

    DENVER, June 03, 2026 (GLOBE NEWSWIRE) -- (www.247marketnews.com) – Cancer treatment has advanced dramatically over the past two decades. Precision medicine, immunotherapy, antibody-drug conjugates, and targeted therapies have transformed outcomes for patients across multiple tumor types. Yet one of oncology's greatest challenges remains largely unsolved. Glioblastoma. Despite billions of dollars invested in research and development, glioblastoma remains one of the deadliest forms of cancer, with patients often facing limited treatment options and poor long-term survival rates. The disease's aggressive nature, combined with the difficulty of delivering therapies into the brain, has mad

    6/3/26 9:28:24 AM ET
    $BNTX
    $IBRX
    $KZIA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Biotechnology: Pharmaceutical Preparations

    Global Data for BioNTech and Bristol Myers Squibb's PD-L1xVEGF-A Bispecific Pumitamig Shows Encouraging Efficacy in Patients with Non-Small Cell Lung Cancer in ROSETTA Lung-02 Trial

    First investigational PD-(L)1xVEGF bispecific immunomodulator to present global data showing encouraging efficacy in combination with chemotherapy in first-line non-small cell lung cancer across PD-L1 expression levels and subtypes, highlighting its potential to set a new standard of carePumitamig plus chemotherapy showed robust and consistent antitumor activity in first-line non-small cell lung cancer at both evaluated dose levels, with higher confirmed objective response rates at the lower dose of 63.6% in the non-squamous and 72.7% in the squamous subtypesPumitamig is advancing through a comprehensive global Phase 3 development program in non-small cell lung cancer, including the actively

    5/30/26 2:15:00 PM ET
    $BMY
    $BNTX
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Biotechnology: Biological Products (No Diagnostic Substances)

    BioNTech to Showcase Progress Across Late-Stage Oncology Pipeline at the 2026 ASCO Annual Meeting

    Pumitamig data from the ongoing Phase 2/3 ROSETTA Lung-02 trial in first-line non-small cell lung cancer mark the third global data set to consistently show encouraging anti-tumor activity for pumitamig in combination with chemotherapyGotistobart Phase 2 overall survival data in patients with platinum-resistant ovarian cancer add to the growing body of evidence supporting its potential as a chemotherapy-free treatment optionContinued advancement of late-stage oncology pipeline with 25+ Phase 2 and Phase 3 clinical trials, including 13 ongoing pivotal trials as well as novel-novel combination trials across major cancer types MAINZ, Germany, May 22, 2026 – BioNTech SE (NASDAQ:BNTX, "BioNTech"

    5/22/26 5:00:00 AM ET
    $BNTX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $BNTX
    SEC Filings

    View All

    SEC Form 6-K filed by BioNTech SE

    6-K - BioNTech SE (0001776985) (Filer)

    6/1/26 7:59:48 AM ET
    $BNTX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form 6-K filed by BioNTech SE

    6-K - BioNTech SE (0001776985) (Filer)

    5/22/26 8:03:17 AM ET
    $BNTX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form 6-K filed by BioNTech SE

    6-K - BioNTech SE (0001776985) (Filer)

    5/15/26 4:18:28 PM ET
    $BNTX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $BNTX
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    BioNTech upgraded by UBS with a new price target

    UBS upgraded BioNTech from Neutral to Buy and set a new price target of $135.00

    5/27/26 8:28:02 AM ET
    $BNTX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Bernstein initiated coverage on BioNTech with a new price target

    Bernstein initiated coverage of BioNTech with a rating of Mkt Perform and set a new price target of $96.00

    5/22/26 8:34:46 AM ET
    $BNTX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    BioNTech downgraded by Leerink Partners with a new price target

    Leerink Partners downgraded BioNTech from Outperform to Market Perform and set a new price target of $113.00

    2/2/26 6:48:45 AM ET
    $BNTX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $BNTX
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by BioNTech SE

    SC 13G/A - BioNTech SE (0001776985) (Subject)

    11/13/24 5:00:57 PM ET
    $BNTX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form SC 13D filed by BioNTech SE

    SC 13D - BioNTech SE (0001776985) (Filed by)

    2/21/24 5:01:33 PM ET
    $BNTX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form SC 13G/A filed by BioNTech SE (Amendment)

    SC 13G/A - BioNTech SE (0001776985) (Subject)

    2/14/24 7:26:25 AM ET
    $BNTX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $BNTX
    Financials

    Live finance-specific insights

    View All

    BioNTech Announces First Quarter 2026 Financial Results and Corporate Update

    Five additional pivotal trials for pumitamig initiated during 2026 in collaboration with Bristol Myers SquibbOncology pipeline strength and combination strategy highlighted through multiple clinical data updates, including pumitamig, gotistobart and antibody-drug conjugate programsCatalyst-rich year ahead with six late-stage pipeline data readouts expected across immunomodulators, antibody-drug conjugate and mRNA cancer immunotherapiesCOVID-19 2026/2027 season variant-adapted vaccine development and commercial preparation underwayOperational efficiency to be enhanced through manufacturing footprint consolidation, supporting strategic capital allocation to further advance its growing oncology

    5/5/26 6:45:00 AM ET
    $BNTX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    BioNTech to Report First Quarter 2026 Financial Results and Corporate Update on May 5, 2026

    MAINZ, Germany, April 21, 2026 (GLOBE NEWSWIRE) -- BioNTech SE (NASDAQ:BNTX, "BioNTech" or "the Company")) will announce its financial results for the first quarter 2026 on Tuesday, May 5, 2026. Additionally, the Company will host a conference call and webcast that day at 8:00 a.m. ET (2:00 p.m. CET) for investors, financial analysts and the general public to discuss its financial results and provide a corporate update.To access the live conference call via telephone, please register via this link. Once registered, dial-in numbers and a PIN will be provided. It is recommended to register at least one day in advance. The slide presentation and audio of the webcast will be available via this l

    4/21/26 6:45:00 AM ET
    $BNTX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    BioNTech Announces Fourth Quarter and Full Year 2025 Financial Results and Corporate Update

    BioNTech on track for a catalyst-rich year with six late-stage data readouts expected across immunomodulators, antibody-drug conjugates and mRNA cancer immunotherapies Increased focus on PD-L11/VEGF-A bispecific immunomodulator pumitamig with eight global Phase 3 clinical trials planned to be ongoing for year-end in collaboration with Bristol Myers Squibb Full year 2025 revenues of €2.9 billion2, net loss of €1.1 billion (adjusted3 net loss of €0.1 billion) and diluted loss per share of €4.70 ($5.314) (adjusted3 diluted loss per share of €0.48 ($0.554)) Strong financial position continues to de-risk execution with cash, cash equivalents and security investments of €17.2 billion5Expect 202

    3/10/26 6:45:00 AM ET
    $BNTX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $BNTX
    Leadership Updates

    Live Leadership Updates

    View All

    BioNTech Announces Appointment of Kylie Jimenez to Management Board as Chief People Officer

    Mainz, Germany, January 28, 2026 (GLOBE NEWSWIRE) – BioNTech SE (NASDAQ:BNTX, "BioNTech" or "the Company")) announced today that the Supervisory Board has appointed Kylie Jimenez to the Management Board as Chief People Officer ("CPO") effective March 1, 2026. The appointment is in line with BioNTech's strategy to become a multi-product oncology company by 2030 and underscores the importance of its global, highly skilled workforce in achieving this objective. In the newly created Management Board role, Kylie Jimenez will be responsible for shaping and leading BioNTech's people strategy and its execution in alignment with the Company's priorities and business goals. She will focus on attractin

    1/28/26 8:00:00 AM ET
    $BNTX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    The $185B Cancer Surge: Why the FDA's Fast-Track Pivot is Scaling a New Immunotherapy Era

    VANCOUVER, British Columbia, Jan. 14, 2026 (GLOBE NEWSWIRE) -- USANewsGroup.com News Commentary – The global immuno-oncology market is set to explode from its current $35 billion level to a massive $185.69 billion by 2035 as the industry moves toward the coordinated activation of the immune system[1]. This surge is being accelerated by the $69.16 billion genomics revolution, which is now integrating advanced profiling into every oncology workflow to pick winning treatments[2]. This strategic push for registration-ready precision assets fuels the 2026 investment case for Oncolytics Biotech Inc. (NASDAQ:ONCY), ImmunityBio (NASDAQ:IBRX), OS Therapies (NYSE-A: OSTX), BioNTech SE (NASDAQ:BNTX),

    1/14/26 10:39:59 AM ET
    $BNTX
    $CMPX
    $IBRX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Biotechnology: Pharmaceutical Preparations

    BioNTech to Host Innovation Series R&D Day on November 11, 2025

    MAINZ, Germany, October 28, 2025 (GLOBE NEWSWIRE) -- BioNTech SE (NASDAQ:BNTX, "BioNTech" or "the Company")), will host an edition of the Company's Innovation Series R&D Day at 09:00 a.m. Eastern Standard Time (3:00 p.m. CET) on Tuesday, November 11, 2025 in New York City, U.S. On the day, members of BioNTech's leadership team will provide an overview of the Company's strategy and clinical progress across its pipeline. Investors, analysts and the interested public are invited to join the event online via this link. A replay of the webcast will be available shortly after the conclusion of the event and archived on the Company's website for one year following the call. The public may also

    10/28/25 7:45:00 AM ET
    $BNTX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care